Welcome to our dedicated page for Tela Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TELA Bio, Inc. (NASDAQ: TELA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its filings offer detailed information on financial performance, capital structure, governance, and material agreements that affect TELA stock.
Investors can review current reports on Form 8-K, where TELA Bio reports material events such as entry into significant credit agreements, registered direct offerings of common stock and pre-funded warrants, and changes in directors and compensatory arrangements. For example, the company has filed 8-Ks describing a senior secured term loan facility with Perceptive Credit Holdings V, LP, the terms of associated warrants to purchase common stock, and the termination of a prior credit and security agreement. Other 8-Ks furnish press releases announcing quarterly financial results and updated investor presentations.
Through its periodic reports (10-K and 10-Q, accessible via EDGAR and summarized on this page), users can analyze TELA Bio’s revenue, gross profit, operating expenses, and net loss, as well as balance sheet items such as cash, long-term debt, and stockholders’ equity. These filings also contain risk factor discussions covering macroeconomic conditions, surgical procedure volumes, competition, product development and manufacturing issues, and reimbursement considerations.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major changes in revenue trends, liquidity, debt covenants, and equity offerings. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and related exhibits appear promptly, while insider and equity-related disclosures such as warrant issuances and director equity awards can be examined alongside the underlying text.
For anyone researching TELA Bio’s regulatory history, financing arrangements, and board-level changes, this filings page offers a structured view of the company’s official disclosures with AI assistance to interpret complex legal and financial language.
TELA Bio reported continued commercial growth with revenue of $20.2 million for the quarter ended June 30, 2025, a 26% increase from $16.1 million a year earlier, and $38.7 million for the six months, up 18% year-over-year. Gross profit for the quarter was $14.1 million. Quarterly net loss narrowed to $9.9 million (EPS -$0.22) from $12.6 million, while the six-month net loss was $21.2 million versus $18.3 million, noting the prior-year six-months included a $7.6 million gain on the sale of the NIVIS product line.
Balance sheet and liquidity show $34.98 million in cash and cash equivalents (restricted cash brings cash per statements of cash flows to $35.24 million), total assets of $67.54 million and total liabilities of $58.35 million. The company carries total debt of $41.38 million (long-term portion $38.05 million) under a MidCap term loan maturing in 2027 with covenants including minimum net revenue tests. Product mix for the quarter was $12.49 million OviTex and $7.33 million OviTex PRS, with international sales of $3.0 million. The company discloses an accumulated deficit of $379.9 million and says it expects to incur losses for the foreseeable future.
TELA Bio, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided an updated corporate slide deck for investor meetings. The Form 8-K identifies the relevant disclosure items as Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure), and lists exhibits including the press release (Exhibit 99.1), the slide deck (Exhibit 99.2) and the Inline XBRL cover page (Exhibit 104). The filing notes these materials are furnished, not filed, and the document is signed by CEO Antony Koblish. The company’s common stock trades on Nasdaq under the symbol TELA and the registrant indicates emerging growth company status.